Initial Statement of Beneficial Ownership (3)
February 16 2021 - 12:08PM
Edgar (US Regulatory)
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0104
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Dexcel Pharma Technologies Ltd. |
2. Date of Event Requiring Statement (MM/DD/YYYY)
2/12/2021
|
3. Issuer Name and Ticker or Trading Symbol
Protalix BioTherapeutics, Inc. [PLX]
|
(Last)
(First)
(Middle)
10 HAKIDMA STREET |
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
_____ Director ___X___ 10% Owner _____ Officer (give title below) _____ Other (specify below)
|
(Street)
YOKNEAM, L3 2069200
(City)
(State)
(Zip)
| 5. If Amendment, Date Original Filed(MM/DD/YYYY)
| 6. Individual or Joint/Group Filing(Check Applicable Line)
___ Form filed by One Reporting Person
_X_ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Beneficially Owned
|
1.Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
Common Stock | 4556031 | D | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 4) | 2. Date Exercisable and Expiration Date (MM/DD/YYYY) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) |
Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Common Stock Purchase Warrants | 3/11/2020 | 3/11/2025 | Common Stock | 2816901 (1) | $2.36 | D | |
Explanation of Responses: |
(1) | The warrants contain a blocker that prohibits the holder from exercising the warrants if such exercise will result in beneficial ownership of more the 9.99% of the Issuer's outstanding common shares by the warrantholder and its affiliates. Since the reporting persons' beneficial ownership percentage is over 9.99%, the warrants are currently not exercisable. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Dexcel Pharma Technologies Ltd. 10 HAKIDMA STREET YOKNEAM, L3 2069200 |
| X |
|
|
Oren Dan 1 DEXCEL STREET OR AKIVA, L3 3060000 |
| X |
|
|
Signatures
|
/s/ Dexcel Pharma Technologies Ltd. by Dan Oren, Executive Chairman | | 2/16/2021 |
**Signature of Reporting Person | Date |
/s/ Dan Oren | | 2/16/2021 |
**Signature of Reporting Person | Date |
Protalix BioTherapeutics (AMEX:PLX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Protalix BioTherapeutics (AMEX:PLX)
Historical Stock Chart
From Sep 2023 to Sep 2024